Meriofert Set

Follicle-Stimulating Hormone; Luteinising Hormone, the active ingredient in Meriofert Set, is a gonadotropin presented as a solution for injection for intramuscular, subcutaneous use. It treats anovulatory infertility in women, supports controlled ovarian stimulation for assisted reproductive technologies, and replaces deficient hormones in hypogonadotropic hypogonadism.

GNH USA supplies Meriofert Set as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert Set acts on the reproductive hormone axis to restore or enhance ovarian function. - Anovulatory infertility: induces follicular development and ovulation in women who do not ovulate spontaneously. - Assisted reproductive technology cycles: provides controlled ovarian stimulation for IVF, ICSI and related procedures. - Hypogonadotropic hypogonadism: replaces deficient gonadotropins to restore normal reproductive hormone function.

Adverse reactions may occur following administration of Meriofert Set.

Common Side Effects: - Injection site pain or erythema - Headache - Nausea or mild abdominal discomfort - Transient ovarian hyperstimulation symptoms

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS) - Thromboembolic events such as deep vein thrombosis - Severe allergic reactions, including anaphylaxis

Use of Meriofert Set requires careful clinical assessment and monitoring. - Patient assessment: evaluate ovarian reserve and baseline hormone levels before initiating therapy. - Monitoring: perform serial ultrasound and estradiol measurements to detect excessive response. - Contraindications: avoid in active ovarian cysts, estrogen‑dependent tumors, or uncontrolled thyroid disease. - Pregnancy: discontinue once pregnancy is confirmed. - Drug interactions: review concomitant use of other gonadotropin‑releasing hormone analogues. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Set may interact with other hormonal or anticoagulant agents.

Major Interactions (Avoid): - GnRH agonists or antagonists: may alter response and increase risk of OHSS. - Hormonal contraceptives: suppress endogenous gonadotropins, reducing efficacy. - Anticoagulants: increased bleeding risk at injection sites.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: may affect ovarian response; monitor thyroid function. - Steroids: can interfere with hormone assays; adjust monitoring as needed. - Insulin or oral hypoglycemics: hormonal changes may affect glucose control; monitor blood sugar levels.